Jennifer C deBruyn, Hien Q Huynh, Anne M Griffiths, Kevan Jacobson, David Mack, Colette Deslandres, Wael El-Matary, Anthony R Otley, Peter C Church, Sally Lawrence, Eytan Wine, Mary Sherlock, Jeffrey Critch, Eric I Benchimol, Prévost Jantchou, Mohsin Rashid, Matthew W Carroll, Kevin Bax, Amanda Ricciuto, Nicholas Carman, Thomas D Walters, Eileen Crowley
BACKGROUND: This study compared real-world effectiveness between adalimumab (ADA) and infliximab (IFX) in children with Crohn's disease (CD). METHODS: Children enrolled into the prospective Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN) National Inception Cohort between 2014 and 2020 who commenced ADA or IFX as first anti-tumor necrosis factor (antiTNF) agent for luminal CD were included. Multivariate logistic regression modelled the propensity of commencing ADA; propensity score matching was used to match IFX-treated children to ADA-treated children...
October 3, 2023: American Journal of Gastroenterology